bydrug.pharmcube.com
【说瘤解癌】发人深思：肺癌L858R 突变合并V834L ... - ByDrug
Jan 8, 2025 ... ByDrug医药新闻摘要⌋ 2025-01-08 07:50，允英：迄今为止规模最大的EGFR 突变肺腺癌基因组数据集汇编中，显示罕见突变和复合突变患者占EGFR 突变患者总数 ...
v834l突变
Searching…
Web results
patents.google.com
人非小细胞肺癌l858r+v834l基因突变原代肿瘤移植瘤模型的应用
一种人非小细胞肺癌L858R+V834L基因突变原代肿瘤移植瘤模型产生的移植瘤能被吉非替尼(Iressa)抑制，本发明的L858R+V834L基因突变原代肿瘤移植瘤模型可用于筛选治疗非小 ...
pmc.ncbi.nlm.nih.gov
EGFR-V834L combined with L858R mutation reduced afatinib ...
Nov 28, 2024 ... We found that the V834L mutation confers resistance to low-concentration EGFR-TKIs in EGFR-L858R-positive tumor cells, and it is possible that ...
zhuanlan.zhihu.com
胚系EGFR突变与家族性肺癌 - 知乎专栏
Oct 25, 2023 ... ... 突变分析。该分析揭示了一个众所周知的致癌突变L858R和一个V834L突变，这两个突变都是EGFR外显子21的替换，并且存在于同一个等位基因(顺式)。V834L ...
www.oncokb.org
Somatic EGFR V834L | OncoKB™
The EGFR exon 21 V834L mutation occurs in the EGFR tyrosine kinase domain. This mutation is found in non-small cell lung cancer (NSCLC).
html.rhhz.net
NSCLC非经典EGFR突变患者临床特点及治疗预后分析
V834L突变是EGFR第834位密码子发生碱基替换(G-T)突变，该位点的氨基酸由缬氨酸(V)转变为亮氨酸(L)。既往报道极少。一项研究发现，V834L不影响TKI治疗的疗效及耐药性，可能与较 ...
www.jto.org
Clinical Outcome and Molecular Analysis of a Chinese Patient ...
EGFR V834L is a rather rare mutation that was previously reported in just two cases of lung adenocarcinoma patients and there is little known about its clinical ...
m-lcbl.amegroups.com
非小细胞肺癌患者肿瘤组织中EGFR和KRAS基因突变的分子 ...
到EGFR基因21外显子突变，包含N826S点突变. 1例(0.08%)，L833F点突变1例(0.08%)，L833V. 点突变1例(0.08%)，V834L点突变1例(0.08%)，. H835L 点突变1 例(0.08%) ， V843I 点突变1 ...
pubmed.ncbi.nlm.nih.gov
EGFR-V834L combined with L858R mutation reduced afatinib ...
Nov 30, 2024 ... These results suggested that V834L cooperates with other coexisting mutations to influence the therapeutic efficacy of EGFR-TKIs.
www.liangyihui.net
【研究解读】吴芳教授：非小细胞肺癌奥希替尼耐药 - 肿瘤资讯
Feb 11, 2022 ... ... V834L。此外，获得性的EGFR 20ins和EGFR扩增伴随亦是奥希替尼的获得性耐药机制。EGFR C797S突变的治疗策略多样化，，当EGFR突变合并C797S，不伴随 ...